![Ileen B. Winick](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ileen B. Winick
Responsable des Ressources Humaines chez
CANDEL THERAPEUTICS, INC.
Profil
Ileen B. Winick currently works at Candel Therapeutics, Inc., as Chief People Officer from 2021.
Ms. Winick also formerly worked at Casebia Therapeutics LLC, as Senior Vice President-Human Resources.
Ms. Winick received her graduate degree from Cornell University and undergraduate degree from the University of Cincinnati (Ohio).
Postes actifs de Ileen B. Winick
| Sociétés | Poste | Début |
|---|---|---|
| CANDEL THERAPEUTICS, INC. | Responsable des Ressources Humaines | 01/01/2021 |
Anciens postes connus de Ileen B. Winick
| Sociétés | Poste | Fin |
|---|---|---|
Casebia Therapeutics LLC
 Casebia Therapeutics LLC Pharmaceuticals: GenericHealth Technology Discovers, develops and commercializes gene-editing therapeutics to treat the genetic causes of bleeding disorders, autoimmune disease | Responsable des Ressources Humaines | - |
Formation de Ileen B. Winick
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
3
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Cincinnati (Ohio)
 University of Cincinnati (Ohio) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Candel Therapeutics, Inc.
 Candel Therapeutics, Inc. BiotechnologyHealth Technology Develops and distributes immunotherapies for the treatment of cancer | Health Technology |
Casebia Therapeutics LLC
Casebia Therapeutics LLC Pharmaceuticals: GenericHealth Technology Discovers, develops and commercializes gene-editing therapeutics to treat the genetic causes of bleeding disorders, autoimmune disease | Health Technology |
